scholarly journals Apalutamide – 10 clinically important facts

Oncoreview ◽  
2021 ◽  
Vol 11 (3(43)) ◽  
pp. 85-88
Author(s):  
Kajetan Juszczak ◽  
Tomasz Drewa
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Hormone Therapy ◽  
Metastatic Prostate Cancer ◽  
Therapeutic Options ◽  
Testosterone Levels ◽  
New Generation ◽  
Receptor Inhibitor

Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over timeduring hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.

scholarly journals Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Marie Lange ◽  
Heidi Laviec ◽  
Hélène Castel ◽  
Natacha Heutte ◽  
Alexandra Leconte ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cognitive Function ◽  
Elderly Patients ◽  
Hormone Therapy ◽  
Metastatic Prostate Cancer ◽  
Trial Protocol ◽  
New Generation

scholarly journals Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Marie Lange ◽  
Heidi Laviec ◽  
Hélène Castel ◽  
Natacha Heutte ◽  
Alexandra Leconte ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cognitive Function ◽  
Elderly Patients ◽  
Hormone Therapy ◽  
Metastatic Prostate Cancer ◽  
Trial Protocol ◽  
New Generation

scholarly journals ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

2015 ◽  
Vol 15 (9) ◽  
pp. 1007-1017 ◽  
Author(s):  
Karim Fizazi ◽  
Laurence Albiges ◽  
Yohann Loriot ◽  
Christophe Massard
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
New Generation ◽  
Receptor Inhibitor

scholarly journals Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Anu-Maarit Moilanen ◽  
Reetta Riikonen ◽  
Riikka Oksala ◽  
Laura Ravanti ◽  
Eija Aho ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Resistance Mechanisms ◽  
Cancer Therapies ◽  
New Generation ◽  
Receptor Inhibitor

scholarly journals Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e042953
Author(s):  
Martin John Connor ◽  
Taimur Tariq Shah ◽  
Katarzyna Smigielska ◽  
Emily Day ◽  
Johanna Sukumar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Randomised Controlled Trial ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Controlled Trial ◽  
Pelvic Lymph Node ◽  
Study Results ◽  
Randomised Controlled

IntroductionSurvival in men diagnosed with de novo synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition of sequential multimodal local and metastasis-directed treatments compared with standard care alone.MethodsA phase II, prospective, multicentre, three-arm randomised controlled trial incorporating an embedded feasibility pilot. All men with new histologically diagnosed, hormone-sensitive, metastatic prostate cancer, within 4 months of commencing ADT and of performance status 0 to 2 are eligible. Patients will be randomised to Control (standard of care (SOC)) OR Intervention 1 (minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)) OR Intervention 2 (cytoreductive radical prostatectomy±PLND OR prostate radiotherapy±pelvic lymph node radiotherapy (PLNRT)). Metastatic burden will be prespecified using the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) definition. Men with low burden disease in intervention arms are eligible for metastasis-directed therapy, in the form of stereotactic ablative body radiotherapy (SABR) or surgery. Standard systemic therapy will be administered in all arms with ADT±upfront systemic chemotherapy or androgen receptor agents. Patients will be followed-up for a minimum of 2 years. Primary outcome: PFS. Secondary outcomes include predictive factors for PFS and overall survival; urinary, sexual and rectal side effects. Embedded feasibility sample size is 80, with 918 patients required in the main phase II component. Study recruitment commenced in April 2019, with planned follow-up completed by April 2024.Ethics and disseminationApproved by the Health Research Authority (HRA) Research Ethics Committee Wales-5 (19/WA0005). Study results will be submitted for publication in peer-reviewed journals.Trial registration numberNCT03763253; ISCRTN58401737

scholarly journals IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer

2019 ◽  
Vol 18 (1) ◽  
pp. 153-165 ◽  
Author(s):  
Janielle P. Maynard ◽  
Onur Ertunc ◽  
Ibrahim Kulac ◽  
Javier A. Baena-Del Valle ◽  
Angelo M. De Marzo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Metastatic Prostate Cancer ◽  
Cancer Aggressiveness
Sign in / Sign up

Export Citation Format

Share Document